Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

Keegan Paradis grew up watching his father, Brendon, lose his vision to a condition no one could name. "My wife said, 'Take ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Dermatomyositis is a chronic autoimmune disease characterised by muscle weakness, skin lesions, and systemic complications.

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of ...

A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that's characterized by mild symptoms or ...